Physician profile
Brian D Marks
NPI 1013982883
$5,538.53
in general payments reported to CMS, 2019-2025
28 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $537 · 2021: $813 · 2022: $633 · 2023: $686 · 2024: $1,043 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,021.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,090.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $784.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $685.33 | 2019-2025 | Repatha, Repatha, Evenity |
| Abbvie INC. | $306.11 | 2021-2025 | |
| Lilly USA, LLC | $232.73 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.73 | 2019-2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $171.64 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $147.93 | 2019-2025 | |
| Exact Sciences Corporation | $146.94 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Intuitive Surgical, INC. | $130.73 | 2025 | |
| Esperion Therapeutics, INC. | $128.26 | 2020-2025 | Nexletol |
| Allergan, INC. | $69.67 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $57.69 | 2020-2021 | |
| Mylan Specialty L.P. | $50.78 | 2019-2021 | |
| Bardy Diagnostics, INC. | $45.66 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40.99 | 2020 | |
| Medtronic, INC. | $35.18 | 2025 | Inceptiv |
| Radius Health, INC. | $27.28 | 2019 | |
| Saluda Medical Americas, INC. | $26.82 | 2024 | Evoke |
| Abbott Laboratories | $24.77 | 2024 | Assurity |
| Axonics, INC. | $19.54 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.99 | 2025 | Nuzyra |
| Ascensia Diabetes Care US INC. | $17.50 | 2025 | |
| Eisai INC. | $17.15 | 2020 | |
| Intra-Sana Laboratories | $16.72 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| E.R. Squibb & Sons, L.L.C. | $15.77 | 2019 | |
| Pfizer INC. | $13.79 | 2023 | |
| Glaxosmithkline, LLC. | $12.84 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.